We used Mendelian randomisation to investigate whether genetic proxies of glucagon-like peptide-1 receptor (GLP-1R) expression are associated with risk of psoriasis and psoriatic arthritis (PsA). Higher GLP-1R expression was associated with reduced susceptibility to psoriasis and PsA, independent of metabolic traits, while no risk-reducing effects were observed for other immune-mediated diseases. These results highlight a disease-specific association between GLP-1 pathway activity and psoriatic disease.
Ramessur et al. (2026) studied this question.